Tech stocks dominated the news after the closing bell on Thursday, but one of the biggest movers was health name BioMarin Pharmaceuticals (BMRN Quote), which surged nearly 13%.
The California-based company disclosed after the market's close that its Kuvan drug, which just received regulatory approval to treat a genetic disorder called phenylketonuria, should generate 2008 revenue of between $35 million and $70 million. That's based on a planned list price of 29 cents per milligram, which the company expects will translate into an average annual therapy cost of $57,000 per patient.
BioMarin shares, which got an upward jolt in Thursday's regular session following the midday approval news, were climbing $3.74 to $33.50 in recent after-hours trading. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,344.84 | 1,095.63 | 2,144.60 | 32.33 |
Oil *
79.29
|
|
UP
34.92
|
UP
4.14
|
UP
6.16
|
UP
0.32
|
10 Yr
3.23%
SPDR Gold
115.65
|
|
+0.34%
|
+0.38%
|
+0.29%
|
+1.00%
|
Data delayed 20 minutes |
Connect with TheStreet